CA2271464A1 - Conditioning for allogeneic stem cell transplantation - Google Patents
Conditioning for allogeneic stem cell transplantation Download PDFInfo
- Publication number
- CA2271464A1 CA2271464A1 CA002271464A CA2271464A CA2271464A1 CA 2271464 A1 CA2271464 A1 CA 2271464A1 CA 002271464 A CA002271464 A CA 002271464A CA 2271464 A CA2271464 A CA 2271464A CA 2271464 A1 CA2271464 A1 CA 2271464A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- donor
- host
- regimen
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 117
- 230000000735 allogeneic effect Effects 0.000 title claims abstract description 60
- 238000011476 stem cell transplantation Methods 0.000 title abstract description 17
- 210000000130 stem cell Anatomy 0.000 claims abstract description 104
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 98
- 238000000034 method Methods 0.000 claims abstract description 92
- 238000002360 preparation method Methods 0.000 claims abstract description 58
- 238000011129 allogeneic cell therapy Methods 0.000 claims abstract description 37
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 115
- 208000024908 graft versus host disease Diseases 0.000 claims description 89
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 67
- 201000010099 disease Diseases 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 31
- 230000001717 pathogenic effect Effects 0.000 claims description 31
- 210000004698 lymphocyte Anatomy 0.000 claims description 30
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical group ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 229960004397 cyclophosphamide Drugs 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 18
- 230000003211 malignant effect Effects 0.000 claims description 18
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical group CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 17
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 17
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 17
- 210000005259 peripheral blood Anatomy 0.000 claims description 17
- 239000011886 peripheral blood Substances 0.000 claims description 17
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 16
- 108010044091 Globulins Proteins 0.000 claims description 16
- 102000006395 Globulins Human genes 0.000 claims description 16
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 16
- 229940100198 alkylating agent Drugs 0.000 claims description 16
- 239000002168 alkylating agent Substances 0.000 claims description 16
- 229960002092 busulfan Drugs 0.000 claims description 16
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 14
- 230000006698 induction Effects 0.000 claims description 12
- 229960000390 fludarabine Drugs 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 210000001185 bone marrow Anatomy 0.000 claims description 10
- 230000001143 conditioned effect Effects 0.000 claims description 10
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 6
- 201000004939 Fanconi anemia Diseases 0.000 claims description 6
- 229940126530 T cell activator Drugs 0.000 claims description 6
- 150000003212 purines Chemical class 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010043391 Thalassaemia beta Diseases 0.000 claims description 5
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 claims description 4
- 208000007502 anemia Diseases 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 abstract description 13
- 208000009329 Graft vs Host Disease Diseases 0.000 description 76
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 25
- 210000001772 blood platelet Anatomy 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 17
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 14
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 14
- 229930105110 Cyclosporin A Natural products 0.000 description 12
- 108010036949 Cyclosporine Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960001265 ciclosporin Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 208000012346 Venoocclusive disease Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 206010068051 Chimerism Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000002559 cytogenic effect Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 238000007469 bone scintigraphy Methods 0.000 description 6
- 239000013256 coordination polymer Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 229930182912 cyclosporin Natural products 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002489 hematologic effect Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010033661 Pancytopenia Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 4
- 229960002963 ganciclovir Drugs 0.000 description 4
- 210000003714 granulocyte Anatomy 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 208000015872 Gaucher disease Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical group ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000000961 alloantigen Effects 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000000781 anti-lymphocytic effect Effects 0.000 description 3
- -1 antibiotics Chemical class 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000009640 blood culture Methods 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 231100000046 skin rash Toxicity 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 229960001196 thiotepa Drugs 0.000 description 3
- 206010043554 thrombocytopenia Diseases 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 102100021906 Cyclin-O Human genes 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 229960004635 mesna Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000004235 neutropenia Diseases 0.000 description 2
- 210000004197 pelvis Anatomy 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007390 skin biopsy Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 235000021476 total parenteral nutrition Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000007325 Amelogenin Human genes 0.000 description 1
- 108010007570 Amelogenin Proteins 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 101150043916 Cd52 gene Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 231100000129 OECD 480 Genetic Toxicology: Saccharomyces cerevisiae, Gene Mutation Assay Toxicity 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010035734 Pneumonia staphylococcal Diseases 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 206010067015 Retroperitoneal lymphadenopathy Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229940086174 acyclovir 200 mg Drugs 0.000 description 1
- 208000026802 afebrile Diseases 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 230000000690 anti-lymphoma Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000007470 bone biopsy Methods 0.000 description 1
- 238000009583 bone marrow aspiration Methods 0.000 description 1
- 229940094219 bonine Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 208000019658 central nervous system non-hodgkin lymphoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- JDZNTUQRMDAIRO-UHFFFAOYSA-N dimethylmyleran Chemical compound CS(=O)(=O)OC(C)CCC(C)OS(C)(=O)=O JDZNTUQRMDAIRO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000604 fetal stem cell Anatomy 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 229940090004 megace Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 239000000537 myeloablative agonist Substances 0.000 description 1
- 229940090009 myleran Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 206010034260 pelvic mass Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 201000003144 pneumothorax Diseases 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000004048 staphylococcal pneumonia Diseases 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/51—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3083396P | 1996-11-15 | 1996-11-15 | |
| US3702497P | 1997-01-31 | 1997-01-31 | |
| US60/030,833 | 1997-01-31 | ||
| US60/037,024 | 1997-01-31 | ||
| PCT/US1997/020946 WO1998020932A2 (en) | 1996-11-15 | 1997-11-14 | Conditioning for allogeneic stem cell transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2271464A1 true CA2271464A1 (en) | 1998-05-22 |
Family
ID=26706512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002271464A Abandoned CA2271464A1 (en) | 1996-11-15 | 1997-11-14 | Conditioning for allogeneic stem cell transplantation |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6544787B1 (enExample) |
| EP (1) | EP1011694A4 (enExample) |
| JP (1) | JP2002514193A (enExample) |
| CA (1) | CA2271464A1 (enExample) |
| IL (1) | IL129573A0 (enExample) |
| WO (1) | WO1998020932A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6428782B1 (en) * | 1997-05-23 | 2002-08-06 | Hadasit Medical Research Services And Development Ltd. | Non-myeloablative tolerogenic treatment |
| JP2001523645A (ja) | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
| ES2351149T3 (es) * | 1998-11-09 | 2011-02-01 | Biogen Idec Inc. | Anticuerpo quimérico dirigido contra cd20, el rituxan, para uso en el tratamiento de la leucemia linfocítica crónica. |
| US20040265285A1 (en) * | 1999-04-15 | 2004-12-30 | Monash University | Normalization of defective T cell responsiveness through manipulation of thymic regeneration |
| US20040258672A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Graft acceptance through manipulation of thymic regeneration |
| US20050042679A1 (en) * | 1999-04-15 | 2005-02-24 | Monash University | Diagnostic indicator of thymic function |
| RU2165765C1 (ru) * | 2000-01-28 | 2001-04-27 | Туманов Владимир Павлович | Способ устранения травматического дефекта барабанной перепонки |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US20060088512A1 (en) * | 2001-10-15 | 2006-04-27 | Monash University | Treatment of T cell disorders |
| WO2005021734A2 (en) * | 2003-09-02 | 2005-03-10 | University Of Massachussets | Generation of hematopoietic chimerism and induction of central tolerance |
| EP1663308A1 (en) * | 2003-09-22 | 2006-06-07 | Xcyte Therapies, Inc | Compositions and methods to accelerate hematologic recovery |
| US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
| US20080279812A1 (en) * | 2003-12-05 | 2008-11-13 | Norwood Immunology, Ltd. | Disease Prevention and Vaccination Prior to Thymic Reactivation |
| WO2006004592A2 (en) * | 2004-05-28 | 2006-01-12 | Mayo Foundation For Medical Education And Research | Methods for autologous stem cell transplantation |
| EP2345412A1 (en) * | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
| EP2201103B1 (fr) * | 2007-10-12 | 2012-06-27 | Université Pierre et Marie Curie (Paris 6) | Traitement de tumeurs par des preparations de lymphocytes t |
| WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
| US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
| WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
| WO2010077313A1 (en) | 2008-12-17 | 2010-07-08 | Sand9, Inc. | Mechanical resonating structures including a temperature compensation structure |
| US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
| US8604888B2 (en) * | 2009-12-23 | 2013-12-10 | Sand 9, Inc. | Oscillators having arbitrary frequencies and related systems and methods |
| US8228127B2 (en) * | 2009-12-23 | 2012-07-24 | Sand 9, Inc. | Oscillators having arbitrary frequencies and related systems and methods |
| ES2686424T5 (es) | 2010-05-04 | 2023-03-27 | Yeda Res & Dev | Inmunoterapia con células alogénicas redireccionadas |
| ES2811529T3 (es) | 2011-12-22 | 2021-03-12 | Yeda Res & Dev | Una terapia de combinación para un injerto estable y a largo plazo usando protocolos específicos para el agotamiento de los linfocitos T/B |
| US20160000811A1 (en) * | 2013-02-20 | 2016-01-07 | Novartis Ag | Treatment of graft versus host disease in transplant patients |
| SG10201907042PA (en) * | 2013-10-08 | 2019-09-27 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| US10800649B2 (en) | 2016-11-28 | 2020-10-13 | Analog Devices International Unlimited Company | Planar processing of suspended microelectromechanical systems (MEMS) devices |
| JP2022505615A (ja) * | 2018-10-31 | 2022-01-14 | マジェンタ セラピューティクス インコーポレイテッド | 造血幹・前駆細胞移植療法の方法 |
| US20210380946A1 (en) * | 2018-11-01 | 2021-12-09 | Children's Hospital Medical Center | Reduced intensity conditioning with melphalan |
| US10843920B2 (en) | 2019-03-08 | 2020-11-24 | Analog Devices International Unlimited Company | Suspended microelectromechanical system (MEMS) devices |
| EP3969905A4 (en) * | 2019-05-16 | 2023-06-14 | Children's Hospital Medical Center | METHODS FOR DETERMINING A CUSTOMIZED FULL DOSE OF MELPHALAN IN A REDUCED-INTENSITY DOSAGE REGIMEN PRIOR TO HEMATOPOIETIC CELL TRANSPLANTATION |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004681B1 (en) * | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
| US5635156A (en) | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US5514364A (en) | 1993-09-13 | 1996-05-07 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| IL112969A (en) | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
-
1997
- 1997-11-14 US US08/995,049 patent/US6544787B1/en not_active Expired - Fee Related
- 1997-11-14 CA CA002271464A patent/CA2271464A1/en not_active Abandoned
- 1997-11-14 EP EP97949457A patent/EP1011694A4/en not_active Withdrawn
- 1997-11-14 JP JP52288698A patent/JP2002514193A/ja not_active Ceased
- 1997-11-14 WO PCT/US1997/020946 patent/WO1998020932A2/en not_active Ceased
- 1997-11-14 IL IL12957397A patent/IL129573A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998020932A3 (en) | 1999-10-21 |
| WO1998020932A2 (en) | 1998-05-22 |
| JP2002514193A (ja) | 2002-05-14 |
| EP1011694A4 (en) | 2000-11-15 |
| IL129573A0 (en) | 2000-02-29 |
| EP1011694A2 (en) | 2000-06-28 |
| US6544787B1 (en) | 2003-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6544787B1 (en) | Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation | |
| ES2561087T3 (es) | Células facilitadoras humanas y usos de las mismas | |
| DE69633668T2 (de) | Allogene zelltherapie für krebs infolge allogener stammzellen transplantation | |
| ES2224122T3 (es) | Inmunoterapia de cancer con linfocitos alogenicos. | |
| USRE39788E1 (en) | Gene therapy | |
| Reisner et al. | Demonstration of clonable alloreactive host T cells in a primate model for bone marrow transplantation. | |
| Peters et al. | Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment | |
| Amos et al. | Sources of human hematopoietic stem cells for transplantation–a review | |
| CN104470542A (zh) | 用于稳定和长期植入的联合疗法 | |
| Orlin et al. | Transfusion-associated giraft-versus-host disease | |
| CN115137752A (zh) | 用于干细胞移植的方法 | |
| Knutsen et al. | Kinetics of T-cell development of umbilical cord blood transplantation in severe T-cell immunodeficiency disorders | |
| ES2606048T3 (es) | Células facilitadoras humanas | |
| US6447767B1 (en) | Non-myeloablative tolerogenic treatment | |
| JPH08510131A (ja) | 癌およびウイルス性疾患を治療するための改変化ｔａｌｌ−１０４細胞の使用 | |
| US20040019390A1 (en) | Methods and compositions for allogeneic transplantation | |
| Buckley | Immunoreconstitution | |
| MacDonald et al. | Donor pretreatment with progenipoietin-1 is superior to G-CSF in preventing graft-versus-host disease after allogeneic stem cell transplantation | |
| JP4106488B2 (ja) | 同種移植片に対する免疫寛容の誘導および／または白血病処置のための、幹細胞およびｃｄ６枯渇幹細胞の使用 | |
| MXPA99004444A (en) | Conditioning for allogeneic stem cell transplantation | |
| US20100129329A1 (en) | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION | |
| Noga | Using allogeneic graft engineering to improve long-term survival | |
| Zorn et al. | Transplantation of CD6-depleted peripheral blood stem cells after DLA-haploidentical bone marrow transplantation contributes to engraftment and tolerance in a preclinical model of stem cell transplantation | |
| US20240108655A1 (en) | Methods of producing mixed chimerism after a solid organ transplant | |
| Party | Aplastic Anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |